ReviewTherapeutic advances in gastroenterology2023
The impact of the COVID-19 pandemic on
Review in Therapeutic advances in gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Twenty-Five-Year Trends in Mortality Associated withMedical sciences (Basel, Switzerland) · 2026Article
- Article
- Incidence of hospital-acquired toxin-producing clostridioides difficile infection between the pre-pandemic (2017-2019) and pandemic (2020-2022): a retrospective cohort study.Archives of public health = Archives belges de sante publique · 2026Article
- Unveiling the role of the respiratory microbiome in long COVID pathogenesis and therapeutics.Chinese medical journal pulmonary and critical care medicine · 2025Article
- Global burden and trends of theAnnals of medicine · 2025Observational
- Increased Antimicrobial Consumption, Isolation Rate, and Resistance Profiles of Multi-Drug ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Comparison ofJournal of clinical medicine · 2025Article
- Clinician Management Preferences forOpen forum infectious diseases · 2025Article
- Article
- Comparative Epidemiological and Clinical Outcomes on COVID-19 and Seasonal Influenza Hospitalized Patients during 2023.Infectious disease reports · 2024Article
- Understanding host immune responses iniMeta · 2024Review
- Therapeutic Perspectives for Microbiota Transplantation in Digestive Diseases and Neoplasia-A Literature Review.Pathogens (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous research has demonstrated that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gains cell entry through the angiotensin-converting enzyme 2 receptor, which is abundantly found throughout the gastrointestinal (GI) tract, resulting in a wide array of GI manifestations of coronavirus disease 2019 (COVID-19). By gaining entry into the intestinal epithelial and stromal cells, SARS-CoV-2 has been observed to cause intestinal inflammation and gut dysbiosis. Alterations in gut microbiota are known to be involved in the pathophysiology of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.